Clinical and epidemiological comparison of patients affected by palmoplantar plaque psoriasis and palmoplantar pustulosis: a case series study

被引:103
作者
Brunasso, A. M. G. [1 ,3 ]
Puntoni, M. [4 ]
Aberer, W. [1 ]
Delfino, C. [5 ]
Fancelli, L. [5 ]
Massone, C. [2 ]
机构
[1] Med Univ Graz, Dept Environm Dermatol & Venereol, A-8036 Graz, Austria
[2] Med Univ Graz, Dept Dermatol, A-8036 Graz, Austria
[3] Galliera Hosp, Sci Directorate, Dept Dermatol, Genoa, Italy
[4] Galliera Hosp, Sci Directorate, Biostat & Clin Trials Unit, Genoa, Italy
[5] Med Univ Florence, Dept Dermatol, Florence, Italy
关键词
PLANTARIS; PALMARIS; LESIONS; ASSOCIATION; USTEKINUMAB; PREVALENCE; ANTIBODIES;
D O I
10.1111/bjd.12223
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Background In 2007 the International Psoriasis Council proposed that palmoplantar pustulosis (PPP) should be considered a separate condition from psoriasis, despite the presence of certain phenotypes common in both diseases. Objectives To describe and compare demographic and clinical characteristics among patients with PPP and palmoplantar plaque psoriasis. Methods This was a retrospective case series study from 2005 to 2010. The following data were obtained: age, sex, family history, smoking habits, nail involvement, joint involvement, disease duration, lesion morphology (plaque or pustular), histological diagnosis, comorbidities, and Physician's Global Assessment (PGA) score for extrapalmoplantar lesions. The sample size calculation indicated that 80 patients, 40 patients for each group (palmoplantar plaque psoriasis and PPP) were needed to see clinically relevant differences between groups. Results Ninety patients were selected, 51 with palmoplantar plaque psoriasis and 39 with PPP. No statistically significant differences were registered between patients affected by PPP and palmoplantar plaque psoriasis as regards age at onset of the disease (48 vs. 44 years; P = 0.4), disease duration (6 vs. 10 years; P = 0.1), family history of psoriasis (28% vs. 33%; P = 0.7), concomitant arthritis (26% vs. 25%; P = 1.0), or smoking habits (54% vs. 41%; P = 0.2). We observed a female predominance (P = 0.01) and a lesser frequency of nail involvement (P = 0.03) in patients affected by PPP. Conclusions Our data suggest a close relationship between PPP and psoriasis. The existing data concerning epidemiology, clinical presentation, genetics, histopathology and pathogenesis do not permit a clear distinction between these two entities, which seem to coincide in many aspects. PPP appears to have a marked predilection among female smokers.
引用
收藏
页码:1243 / 1251
页数:9
相关论文
共 37 条
[1]   A retrospective analysis of treatment responses of palmoplantar psoriasis in 114 patients [J].
Adisen, E. ;
Tekin, O. ;
Guelekon, A. ;
Guerer, M. A. .
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2009, 23 (07) :814-819
[2]   Palmoplantar pustulosis should not be considered as a variant of psoriasis [J].
Ammoury, A. ;
El Sayed, F. ;
Dhaybi, R. ;
Bazex, J. .
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2008, 22 (03) :392-393
[3]  
[Anonymous], COCHRANE DATABASE SY
[4]   Genetic analysis of PSORS1 distinguishes guttate psoriasis and palmoplantar pustulosis [J].
Asumalahti, K ;
Ameen, M ;
Suomela, S ;
Hagforsen, E ;
Michaëlsson, G ;
Evans, J ;
Munro, M ;
Veal, C ;
Allen, M ;
Leman, J ;
Burden, AD ;
Kirby, B ;
Connolly, M ;
Griffiths, CEM ;
Trembath, RC ;
Kere, J ;
Saarialho-Kere, U ;
Barker, JNWN .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2003, 120 (04) :627-632
[5]  
Barber HW., 1930, BRIT J DERMATOL, V42, P500, DOI DOI 10.1111/J.1365-2133.1930.TB09380.X
[6]   Treatment of palmoplantar psoriasis with infliximab: a randomized, double-blind placebo-controlled study [J].
Bissonnette, R. ;
Poulin, Y. ;
Guenther, L. ;
Lynde, C. W. ;
Bolduc, C. ;
Nigen, S. .
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2011, 25 (12) :1402-1408
[7]   Can we really separate palmoplantar pustulosis from psoriasis? [J].
Brunasso, A. M. G. ;
Massone, C. .
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2010, 24 (05) :619-621
[8]   Efalizumab for severe palmo-plantar psoriasis: an open-label pilot trial in five patients [J].
Brunasso, A. M. G. ;
Salvini, C. ;
Massone, C. .
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2009, 23 (04) :415-419
[9]  
Burden AD, 1996, BRIT J DERMATOL, V134, P1079, DOI 10.1111/j.1365-2133.1996.tb07946.x
[10]   RECALCITRANT PUSTULAR PSORIASIS SUCCESSFULLY TREATED WITH ADALIMUMAB [J].
Chaves Alvarez, Antonio ;
Rodriguez-Nevado, Isabel ;
De Argila, Diego ;
Peral Rubio, Francisco ;
Rovira, Isabel ;
Torrelo, Antonio ;
Zambrano, Antonio .
PEDIATRIC DERMATOLOGY, 2011, 28 (02) :195-197